Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403830 | 0.85 | CYP19A1 (0.52) | GSK3BCYP19A1CYP2A6ALDH1A1CA12 | |
| SCHEMBL4003869 | 0.84 | GSK3B (0.48) | GSK3BCYP19A1CYP2A6ALDH1A1CA12 | |
| SCHEMBL324969 | 0.84 | CA2 (0.46) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL9913657 | 0.81 | CA2 (0.39) | GSK3BCYP19A1CYP2A6ALDH1A1CA12 | |
| SCHEMBL9913645 | 0.81 | CYP19A1 (0.37) | CYP19A1CYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL9913659 | 0.81 | CYP2A6 (0.39) | CYP19A1CYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL8773276 | 0.78 | MMP3 (0.52) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL8974055 | 0.78 | MMP3 (0.52) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL10300064 | 0.78 | CA2 (0.41) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL13019484 | 0.78 | MMP3 (0.52) | CYP2A6ALDH1A1CA12CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | disclosed |
| US-7465749-B2 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS, LTD. (IL) | 2008-12-16 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | GSK3B 1167/4885CYP19A1 1/4885CYP2A6 189/4885 |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | CYP19A1, CYP4B1, CYP3A4 | GSK3B 449/4885CYP19A1 1/4885CYP2A6 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.